Document:

EX-4.5.2

 Exhibit 4.5.2 

FIRST AMENDMENT TO WARRANT TO PURCHASE STOCK 

[October 26, 2011 Warrant] 
 THIS
FIRST AMENDMENT TO WARRANT TO PURCHASE STOCK (this “Amendment”’) is deemed effective as of July 27, 2012, by and between SVB FINANCIAL GROUP (“SVB Financial Group” or
“Holder”) and CARBYLAN BIOSURGERY, INC., a Delaware corporation (the “Company”). 

RECITALS 

A.         The Company issued the Warrant to Purchase Stock to Silicon Valley Bank on
October 26, 2011, which Silicon Valley Bank subsequently assigned to SVB Financial Group, (as the same may from time to time be further amended, modified, supplemented or restated, the “Warrant”). 

B.         Silicon Valley has extended credit to the Company for the purposes permitted in the
Loan and Security Agreement dated as of October 26, 2011 between the Company and Silicon Valley Bank, as amended (as amended, the “Loan Agreement”). In connection therewith, SVB Financial Group and the Company agree to
amend the Warrant as set forth herein. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable consideration, the
receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows: 

1.         Definitions. Capitalized terms used but not defined in this Amendment shall have the
meanings given to them in the Warrant. 
 2.         Amendments to Warrant. 

  2.1         Definitions. 

(a)         The following definitions on page 1 of the Warrant are amended and restated in
their entirety to read as follows: 
  

			
	Number of Shares: (i)	  	144,928 shares, plus (ii) if the Availability Extension Request (as defined in the Loan Agreement) is made, an additional 28,986 shares.

 
			
	Expiration Date: July 27, 2022
	Credit Facility:	  	This Warrant to Purchase Stock (“Warrant”) is issued in connection with that certain Loan and Security Agreement dated as of October 26, 2011, as amended by that certain First Amendment to Loan and Security
Agreement dated as of July 27, 2012 between Silicon Valley Bank and the Company (as amended, the “Loan Agreement”).

 3.         General. Except as amended by the amendments
set forth in Section 2 above, the Warrant remains in full force and effect. This Amendment may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute one and the same
instrument. This Amendment shall be deemed effective upon the due execution and delivery to SVB Financial Group of this Amendment by each party hereto. 

[Signature page follows.] 

  
 1 

 IN WITNESS WHEREOF, the parties hereto have caused this First Amendment to Warrant to
Purchase Stock to be duly executed and delivered as of the date first written above. 
  

											
	GOLD HILL	  		  	BORROWER	  	
				
	SVB Financial Group	  		  	Carbylan Biosurgery, Inc.	  	
						
	By:	  	/s/ Kevin Longo	  		  	By:	  	/s/ George Y. Daniloff	  	
	Name:	  	 Kevin Longo
	  		  	Name:	  	 George Y. Daniloff
	  	

											
	Title:	  	 Relationship Manager
	  		  	Title:	  	 President & CEO
	  	

 [First Amendment to October 26, 2011 Warrant] 

  
 2EX-4.5.3

 Exhibit 4.5.3 

SECOND AMENDMENT TO WARRANT TO PURCHASE STOCK 

[October 26, 2011 Warrant] 

THIS SECOND AMENDMENT TO WARRANT TO PURCHASE STOCK (this “Amendment”) is deemed effective as of
February 12th, 2013, by and between SVB FINANCIAL GROUP (“SVB Financial Group” or “Holder”) and CARBYLAN BIOSURGERY, INC., a Delaware corporation (the “Company”).

 RECITALS 

A.       The Company issued the Warrant to Purchase Stock to Silicon Valley Bank on October 26,
2011, which Silicon Valley Bank subsequently assigned to SVB Financial Group, (as the same may from time to time be further amended, modified, supplemented or restated, the “Warrant”). 

B.       Silicon Valley has extended credit to the Company for the purposes permitted in the Loan and
Security Agreement dated as of October 26, 2011 between the Company and Silicon Valley Bank, as amended (as amended, the “Loan Agreement”). In connection therewith, SVB Financial Group and the Company agree to amend the
Warrant as set forth herein. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which
is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows; 

1.       Definitions. Capitalized terms used but not defined in this Amendment shall have the meanings
given to them in the Warrant. 
 2.       Amendments to Warrant. 

2.1       Definitions. 

(a)       The following definitions on page 1 of the Warrant are amended and restated in their entirety
to read as follows: 
 Number of Shares: 199,569 shares 

Warrant Price: $1.2026 

3.       General. Except as amended by the amendments set forth in Section 2 above, the
Warrant remains m full force and effect. This Amendment may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute one and the same instrument. This Amendment shall be deemed effective
upon the due execution and delivery to SVB Financial Group of this Amendment by each party hereto. 
 [Signature page follows.] 

 IN WITNESS WHEREOF, the parties hereto have caused this Second Amendment to Warrant to
Purchase Stock to be duly executed and delivered as of the date first written above. 
  

									
	 SVB FINANCIAL GROUP
  

SVB Financial Group
	 		 	 BORROWER
  

Carbylan Biosurgery, Inc.

					
	By:	 	 /s/ Michael D. Kruse         
	 		 	By:	 	 /s/ George Daniloff
        

									
	Name:	 	   Michael D. Kruse
	 		 	Name:	 	   George Daniloff

									
	Title:	 	   Treasurer
	 		 	Title:	 	   President and CEO

 [Second Amendment to October 26, 2011 Warrant] 

  
 2EX-4.6

 Exhibit 4.6 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”). OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND
SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 
 WARRANT TO
PURCHASE STOCK 
 Company: CARBYLAN BIOSURGERY, INC. 

Number of Shares: as set forth below 
 Type/Series of
Stock: as set forth below 
 Warrant Price: as set forth below 

Issue Date:     February 15, 2013 

Expiration Date: February 15, 2023             See also Section 5.1(b). 

Credit Facility: This Warrant to Purchase Stock (“Warrant”) is issued in
connection with that certain Second Amendment to Loan and Security Agreement of even date hereof, which amends that certain Loan and Security Agreement as of October 26, 2011 between Silicon Valley Bank and the Company (as amended, the
“Loan Agreement”). 
 THIS WARRANT CERTIFIES THAT, for good and valuable consideration,
SILICON VALLEY BANK (together with any successor or permitted assignee or transferee of this Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase the number of fully paid and non-assessable
shares (the “Shares”) of the above-stated Type/Series of Stock (the “Class”) of the above-named company (the “Company”) at the above-stated Warrant Price, all as set forth above
and as adjusted pursuant to Section 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant. Reference is made to Section 5.4 of this Warrant whereby Silicon Valley Bank shall transfer this
Warrant to its parent company, SVB Financial Group. This Warrant is in addition to that certain Warrant to purchase Stock issued by the Company on October 26, 2011, as amended from time to time. 

As used herein: 

“Class of Stock” means at Bank’s option: (i) the Company’s Series B Preferred Stock, or
(ii) Next Round Stock; provided that until the Next Round occurs, the Class of Stock shall be the Company’s Series B Preferred Stock. 

“Next Round” means the Company’s next sale of its convertible preferred stock (other than Series B
Preferred Stock) to purchasers which include venture capital investors. 
 “Next Round Price” means the
lowest effective price per share (on a common stock equivalent basis and taking into account any securities issued together with the preferred stock) at which shares of the Company’s convertible preferred stock are sold in the Next Round. 

 “Next Round Stock” means the Company’s convertible
preferred stock issued and sold in the Next Round. 
 “Number of Shares” means the cumulative, aggregate
number of shares of the Company’s Series B Preferred Stock equal to (x) 4.0% of the original principal amount of each Growth Capital Advance (as defined in the Loan Agreement) made to the Company by Silicon Valley Bank pursuant to the Loan
Agreement (as defined above) divided by (y) the Warrant Price. 
 “Series B Price” means $1.2026 per
share. 
 “Warrant Price” means: (i) if the Class of Stock is Series B Stock, the Series B Price, or
(ii) if the Class of Stock is Next Round Stock, the Next Round Price. 
 SECTION 1. EXERCISE. 

1.1.     Method of Exercise.   Holder may at any time and from time to time exercise
this Warrant, in whole or in part, by delivering to the Company the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto as Appendix 1 and, unless Holder is exercising this Warrant
pursuant to a cashless exercise set forth in Section 1.2, a check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares
being purchased. 
 1.2.     Cashless Exercise.   On any exercise of this Warrant, in
lieu of payment of the aggregate Warrant Price in the manner as specified in Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Shares equal to the value of this Warrant, or
portion hereof as to which this Warrant is being exercised. Thereupon, the Company shall issue to the Holder such number of fully paid and non-assessable Shares as are computed using the following formula: 

X = Y(A-B)/A 
 where: 

 

					
		 	X =	  	 the number of Shares to be issued to the Holder;

			
		 	Y =	  	 the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company in payment of the aggregate
Warrant Price);

			
		 	A=	  	 the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and

			
		 	B =	  	 the Warrant Price.

 1.3.     Fair Market Value. If the Company’s common stock is
then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or over-the-

  
 -2- 

 
counter market (a “Trading Market”) and the Class is common stock, the fair market value of a Share shall be the closing price or last sale price of a share of common
stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company. If the Company’s common stock is then traded in a Trading Market and the Class is a
series of the Company’s convertible preferred stock, the fair market value of a Share shall be the closing price or last sale price of a share of the Company’s common stock reported for the Business Day immediately before the date on which
Holder delivers this Warrant together with its Notice of Exercise to the Company multiplied by the number of shares of the Company’s common stock into which a Share is then convertible. If the Company’s common stock is not traded in a
Trading Market, the Board of Directors of the Company shall determine the fair market value of a Share in its reasonable good faith judgment. 

1.4.     Delivery of Certificate and New Warrant.   Within a reasonable time after
Holder exercises this Warrant in the manner set forth in Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise and, if this Warrant has not been fully exercised
and has not expired, a new warrant of like tenor representing the Shares not so acquired. 
 1.5.    
Replacement of Warrant.   On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity
agreement reasonably satisfactory in form, substance and amount to the Company or, in the case of mutilation, on surrender of this Warrant to the Company for cancellation, the Company shall, within a reasonable time, execute and deliver to Holder,
in lieu of this Warrant, a new warrant of like tenor and amount. 
 1.6.     Treatment of Warrant
Upon Acquisition of Company. 
     (a)     Acquisition.
    For the purpose of this Warrant, “Acquisition” means any transaction or series of related transactions involving: (i) the sale, lease, exclusive license, or other disposition of all or
substantially all of the assets of the Company (ii) any merger or consolidation of the Company into or with another person or entity (other than a merger or consolidation effected exclusively to change the Company’s domicile), or any other
corporate reorganization, in which the stockholders of the Company in their capacity as such immediately prior to such merger, consolidation or reorganization, own less than a majority of the Company’s (or the surviving or successor
entity’s) outstanding voting power immediately after such merger, consolidation or reorganization; or (iii) any sale or other transfer by the stockholders of the Company of shares representing at least a majority of the Company’s
then-total outstanding combined voting power. 
     (b)     Treatment of
Warrant at Acquisition.     In the event of an Acquisition in which the consideration to be received by the Company’s stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and
Marketable Securities (a “Cash/Public Acquisition”), either (i) Holder shall exercise this Warrant pursuant to Section 1.1 and/or 1.2 and such exercise will be deemed effective immediately prior to and contingent
upon the consummation of such Acquisition or (ii) if Holder elects not to exercise the Warrant, this Warrant will expire immediately prior to the consummation of such Acquisition. 

  
 -3- 

     (c)     The Company shall provide
Holder with written notice of its request relating to the Cash/Public Acquisition (together with such reasonable information as Holder may reasonably require regarding the treatment of this Warrant in connection with such contemplated Cash/Public
Acquisition giving rise to such notice), which is to be delivered to Holder not less than seven (7) Business Days prior to the closing of the proposed Cash/Public Acquisition. In the event the Company does not provide such notice, then if,
immediately prior to the Cash/Public Acquisition, the fair market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above would be greater than the Warrant Price in effect on
such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the Company
shall promptly notify the Holder of the number of Shares (or such other securities) issued upon such exercise to the Holder and Holder shall be deemed to have restated each of the representations and warranties in Section 4 of the Warrant as
the date thereof. 
     (d)     Upon the closing of any Acquisition other than a
Cash/Public Acquisition defined above, the acquiring, surviving or successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or other property as would have been paid
for the Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time in accordance with the provisions of
this Warrant. 
     (e)     As used in this Warrant, “Marketable
Securities” means securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), and is then current in its filing of all required reports under the Exchange Act and in compliance with all other public information reporting requirements of the Securities and Exchange
Commission or any other federal agency at the time administering the Exchange Act which reporting requirements are conditions to the availability of Rule 144 for the sale of the issuer’s Common Stock; (ii) the class and series of shares or
other security of the issuer that would be received by Holder in connection with the Acquisition were Holder to exercise this Warrant on or prior to the closing thereof is then traded in a Trading Market, and (iii) Holder would be able to
publicly re-sell, no later than six (6) months following the closing of such Acquisition, all of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise this Warrant in full
on or prior to the closing of such Acquisition. 
 SECTION 2. ADJUSTMENTS TO THE SHARES AND WARRANT PRICE. 

2.1.     Stock Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution
on the outstanding shares of the Class payable in common stock or other securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without additional cost to Holder, the total number
and kind of securities and property which Holder would have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding shares of the Class by reclassification or
otherwise into a greater number of shares, the number of Shares 

  
 -4- 

 
purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Class are combined or consolidated, by
reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased. 

2.2.     Reclassification, Exchange, Combinations or Substitution.     Upon
any event whereby all of the outstanding shares of the Class are reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then from and after the consummation of such
event, this Warrant will be exercisable for the number, class and series of Company securities that Holder would have received had the Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter
from time to time in accordance with the provisions of this Warrant. The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations substitutions, replacements or other similar events. 

2.3.     Conversion of Preferred Stock.   If the Class is a class and series of the
Company’s convertible preferred stock, in the event that all outstanding shares of the Class are converted, automatically or by action of the holders thereof, into common stock pursuant to the provisions of the Company’s Certificate of
Incorporation, including, without limitation, in connection with the Company’s initial, underwritten public offering and sale of its common stock pursuant to an effective registration statement under the Act (the “IPO”),
then from and after the date on which all outstanding shares of the Class have been so converted, this Warrant shall be exercisable for such number of shares of common stock into which the Shares would have been converted had the Shares been
outstanding on the date of such conversion, and the Warrant Price shall equal the Warrant Price in effect as of immediately prior to such conversion divided by the number of shares of common stock into which one Share would have been converted, all
subject to further adjustment thereafter from time to time in accordance with the provisions of this Warrant. 

2.4.     Adjustments for Diluting Issuances.   Without duplication of any adjustment
otherwise provided for in this Section 2, the number of shares of common stock issuable upon conversion of the Shares shall be subject to anti-dilution adjustment from time to time in the manner set forth in the Company’s Articles or
Certificate of Incorporation as if the Shares were issued and outstanding on and as of the date of any such required adjustment. 

2.5.     No Fractional Share.   No fractional Share shall be issuable upon exercise of
this Warrant and the number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company shall eliminate such fractional Share interest by paying Holder
in cash the amount computed by multiplying the fractional interest by (i) the fair market value (as determined in accordance with Section 1.3 above) of a frill Share, less (ii) the then-effective Warrant Price. 

2.6.     Notice/Certificate as to Adjustments.     Upon each adjustment of the
Warrant Price, Class and/or number of Shares, the Company, at the Company’s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, Class and/or number of Shares and facts upon which
such adjustment is based. The Company shall, upon written request from Holder, furnish Holder with a certificate of its Chief 

  
 -5- 

 
Financial Officer, including computations of such adjustment and the Warrant Price, Class and number of Shares in effect upon the date of such adjustment. 

SECTION 3. REPRESENTATIONS AND COVENANTS OF THE COMPANY. 

3.1.     Representations and Warranties.   The Company represents and warrants to, and
agrees with, the Holder as follows: 
     (a)     The initial Warrant Price
referenced on the first page of this Warrant is not greater than the price per share at which shares of the Class were last sold and issued prior to the Issue Date hereof in an arms-length transaction in which at least $500,000 of such shares were
sold. 
     (b)     All Shares which may be issued upon the exercise of this
Warrant, and all securities, if any, issuable upon conversion of the Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and non-assessable, and free of any liens and encumbrances (other than created by Holder) except for
restrictions on transfer provided for herein or under applicable federal and state securities laws. The Company covenants that it shall at all times cause to be reserved and kept available out of its authorized and unissued capital stock such number
of shares of the Class, common stock and other securities as will be sufficient to permit the exercise in frill of this Warrant and the conversion of the Shares into common stock or such other securities. 

    (c)     The Company’s capitalization table attached hereto as Schedule 1 is
true and complete, in all material respects, as of the Issue Date. 
 3.2.     Notice of Certain
Events.   If the Company proposes at any time to: 
     (a)    
declare any dividend or distribution upon the outstanding shares of the Class or common stock, whether in cash, property, stock, or other securities and whether or not a regular cash dividend; 

    (b)     offer for subscription or sale pro rata to the holders of the outstanding
shares of the Class any additional shares of any class or series of the Company’s stock (other than pursuant to contractual pre-emptive rights); 

    (c)     effect any reclassification, exchange, combination, substitution,
reorganization or recapitalization of the outstanding shares of the Class; 

    (d)     effect an Acquisition or to liquidate, dissolve or wind up; or 

    (e)     effect an IPO; 

then, in connection with each such event, the Company shall give Holder: 

    (1)     at least seven (7) Business Days prior written
notice of the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which the holders of outstanding shares of the 

  
 -6- 

 
Class will be entitled thereto) or for determining rights to vote, if any, in respect of the matters referred to in (a) and (b) above; 

    (2)     in the case of the matters referred to in (c) and
(d) above at least seven (7) Business Days prior written notice of the date when the same will take place (and specifying the date on which the holders of outstanding shares of the Class will be entitled to exchange their shares for the
securities or other property deliverable upon the occurrence of such event); and 

    (3)     with respect to the IPO, at the same time that notice of
the IPO is provided to stockholders of the Company with registration rights. 
 Reference is made to Section 1.6(c) whereby this
Warrant will be deemed to be exercised pursuant to Section 1.2 hereof if the Company does not give written notice to Holder of a Cash/Public Acquisition as required by the terms hereof. Company will also provide information requested by Holder
that is reasonably necessary to enable Holder to comply with Holder’s accounting or reporting requirements. 
 SECTION 4.
REPRESENTATIONS. WARRANTIES OF THE HOLDER. 
 The Holder represents and warrants to the Company as follows: 

4.1.     Purchase for Own Account.   This Warrant and the securities to be acquired upon
exercise of this Warrant by Holder are being acquired for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that it has not
been formed for the specific purpose of acquiring this Warrant or the Shares. 
 4.2.     Disclosure
of Information.   Holder is aware of the Company’s business affairs and financial condition and has received or has had full access to all the information it considers necessary or appropriate to make an informed investment
decision with respect to the acquisition of this Warrant and its underlying securities. Holder further has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant
and its underlying securities and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to Holder or to which
Holder has access. 
 4.3.     Investment Experience.   Holder understands that the
purchase of this Warrant and its underlying securities involves substantial risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s
investment in this Warrant and its underlying securities and has such knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities
and/or has a preexisting personal or business relationship with the Company and certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial
circumstances of such persons. 

  
 -7- 

 4.4.     Accredited Investor Status.
  Holder is an “accredited investor” within the meaning of Regulation D promulgated under the Act. 

4.5.     The Act.   Holder understands that this Warrant and the Shares issuable upon
exercise hereof have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as expressed herein. Holder
understands that this Warrant and the Shares issued upon any exercise hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such registration and
qualification are otherwise available. Holder is aware of the provisions of Rule 144 promulgated under the Act. 

4.6.     Market Stand-off Agreement.   The Holder agrees that the Shares shall be
subject to the Market Standoff provisions in Section 5 of the Company’s Amended and Restated Registration Rights Agreement dated as of December 21, 2012, as amended from time to time. 

4.7.     No Voting Rights.   Holder, as a Holder of this Warrant, will not have any
voting rights until the exercise of this Warrant. 
 SECTION 5. MISCELLANEOUS. 

5.1.     Term and Automatic Conversion Upon Expiration. 

    (a)     Term.   Subject to the provisions of Section 1.6
above, this Warrant is exercisable in whole or in part at any time and from time to time on or before 6:00 PM, Pacific time, on the Expiration Date and shall be void thereafter. 

    (b)     Automatic Cashless Exercise upon Expiration.   In the
event that, upon the Expiration Date, the fair market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in effect on such date, then
this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the Company shall, within a
reasonable time, deliver a certificate representing the Shares (or such other securities) issued upon such exercise to Holder. 

5.2.     Legends.   The Shares (and the securities issuable, directly or indirectly,
upon conversion of the Shares, if any) shall be imprinted with a legend in substantially the following form: 

THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “ACT”). OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO SILICON VALLEY BANK DATED OCTOBER 26, 2011, MAY NOT BE OFFERED, SOLD,
PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS 

  
 -8- 

 
OR IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 

5.3.     Compliance with Securities Laws on Transfer.   This Warrant and the Shares
issuable upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part except in compliance with applicable federal and state
securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company
shall not require Holder to provide an opinion of counsel if the transfer is to SVB Financial Group (Silicon Valley Bank’s parent company) or any other affiliate of Holder, provided that any such transferee is an “accredited investor”
as defined in Regulation D promulgated under the Act. Additionally, the Company shall also not require an opinion of counsel if there is no material question as to the availability of Rule 144 promulgated under the Act. 

5.4.     Transfer Procedure.   After receipt by Silicon Valley Bank of the executed
Warrant, Silicon Valley Bank will transfer all of this Warrant to its parent company, SVB Financial Group. By its acceptance of this Warrant, SVB Financial Group hereby makes to the Company each of the representations and warranties set forth in
Section 4 hereof and agrees to be bound by all of the terms and conditions of this Warrant as if the original Holder hereof. Subject to the provisions of Section 5.3 and upon providing the Company with written notice, SVB Financial Group
and any subsequent Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable directly or indirectly, upon conversion of the Shares, if any) to any transferee, provided, however,
in connection with any such transfer, SVB Financial Group or any subsequent Holder will give the Company notice of the portion of the Warrant being transferred with the name, address and taxpayer identification number of the transferee and Holder
will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if applicable); and provided further, that any subsequent transferee other than SVB Financial Group shall agree in writing with the Company to be bound by all
of the terms and conditions of this Warrant. Notwithstanding any contrary provision herein, at all times prior to the IPO, Holder may not, without the Company’s prior written consent, transfer this Warrant or any portion hereof, or any Shares
issued upon any exercise hereof, or any shares or other securities issued upon any conversion of any Shares issued upon any exercise hereof, to any person or entity who directly competes with the Company, except in connection with an Acquisition of
the Company by such a direct competitor. 
 5.5.     Notices.   All notices and other
communications hereunder from the Company to the Holder, or vice versa, shall be deemed delivered and effective (i) when given personally, (ii) on the third (3rd) Business Day after
being mailed by first-class registered or certified mail, postage prepaid, (iii) upon actual receipt if given by facsimile or electronic mail and such receipt is confirmed in writing by the recipient, or (iv) on the first Business Day
following delivery to a reliable overnight courier service, courier fee prepaid, in any case at such address as may have been furnished to the Company or Holder, as the case may be, in writing by the Company or such Holder from time to time in
accordance with the provisions of this Section 

  
 -9- 

 
5.5. All notices to Holder shall be addressed as follows until the Company receives notice of a change of address in connection with a transfer or otherwise: 

SVB Financial Group 
 Attn:
Treasury Department 
 3003 Tasman Drive, HC 215 

Santa Clara, CA 95054 

Telephone: (408) 654-7400 

Facsimile: (408) 988-8317 

Email address: derivatives@svb.com 

Notice to the Company shall be addressed as follows until Holder receives notice of a change in address: 

Carbylan Biosurgery, Inc. 

Attn: Chief Business Officer 

3181 Porter Drive 
 Palo Alto,
CA 94304 
 Telephone: 650 855 6777 

Facsimile: 650 855 9119 
 Email:
gsaul@carbylan.com 
 5.6.     Waiver.   This Warrant and any term hereof may be
changed, waived, discharged or terminated (either generally or in a particular instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or
termination is sought. 
 5.7.     Attorney’s Fees.   In the event of any dispute
between the parties concerning the terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 

5.8.     Counterparts; Facsimile/Electronic Signatures.   This Warrant may be executed
in counterparts, all of which together shall constitute one and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an original signature page with regards to any agreement subject
to the terms hereof or any amendment thereto. 
 5.9.     Governing Law.   This
Warrant shall be governed by and construed in accordance with the laws of the State of California, without giving effect to its principles regarding conflicts of law. 

5.10.   Headings.   The headings in this Warrant are for purposes of reference only and shall not
limit or otherwise affect the meaning of any provision of this Warrant. 
 5.11.   Business Days.
  “Business Day” is any day that is not a Saturday, Sunday or a day on which Silicon Valley Bank is closed. 

[Remainder of page left blank intentionally] 

[Signature page follows] 

  
 -10- 

 IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be
executed by their fully authorized representatives effective as of the Issue Date written above. 
 “COMPANY” 

CARBYLAN BIOSURGERY, INC. 
 By:   /s/ George
Daniloff                    
 Name:   George
Daniloff                    

            (Print) 

Title:   President and CEO                  

“HOLDER” 
 SILICON VALLEY BANK 

By:   /s/ Kevin Longo        
               
 Name:   Kevin
Longo                        

            (Print) 

Title:   Relationship Manager           

  
 -11- 

 APPENDIX 1 

NOTICE OF EXERCISE 

1.         The undersigned Holder hereby exercises its right purchase
                         shares of the Common/Series
             Preferred [circle one] Stock of
                         (the “Company”) in accordance with the attached Warrant To Purchase
Stock, and tenders payment of the aggregate Warrant Price for such shares as follows: 
 [      ]
    check in the amount of $                     payable to order of the Company enclosed herewith 

[      ]     Wire transfer of immediately available funds to the Company’s account 

[      ]     Cashless Exercise pursuant to Section 1.2 of the Warrant 

[      ]     Other [Describe]
                                         
                                         
                                         
  
 2.         Please issue a certificate or certificates representing the Shares in
the name specified below: 
  

					
		  	Holder’s Name	  	
			
		  	 	  	
			
		  		  	
		  	(Address)	  	

 3.         By its execution below and for the benefit
of the Company, Holder hereby restates each of the representations and warranties in Section 4 of the Warrant to Purchase Stock as of the date hereof. 
  

							
		  		  	HOLDER:	  	
				
		  		  	                                      
               	  	
				
		  		  	By:                                     
           	  	
				
		  		  	Name:                                     
      	  	
				
		  		  	Title:                                     
        	  	
				
		  		  	(Date):                                     
     	  	

  
 Appendix 1 

 SCHEDULE 1 

Company Capitalization Table 

Intentionally Omitted 

  
 Schedule 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}]]